For Friday, February 24th
NHYT, OREX, GRNE, MELA, DTRO, OBJE
Our Stocks to Watch tomorrow include Neohydro Technologies Corp. (OTCBB: NHYT), Orexigen Therapeutics Inc. (NASDAQ: OREX), Green Endeavors Inc. (OTCQB: GRNE), MELA Sciences Inc. (NASDAQ: MELA), Deltron Inc. (OTCBB: DTRO) and Obscene Interactive LLC (OTCBB: OBJE).
NEOHYDRO TECHNOLOGIES CORPORATION (OTCBB: NHYT)
"Up 72.50% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/NHYT.php
Neohydro Technologies Corp. engages in the acquisition and exploration of mineral resources. It intends to explore for gold. It owns interest in the Rio Lode Claim, which is located within the Yellow Pine Mining District of Clark County, Nevada. The company, formerly known as Rioridge Resources Corp., was founded in 2007 and is based in Piscataway, New Jersey.
NHYT News:
No recent news items for Neohydro Technologies Corp. (OTCBB: NHYT).
OREXIGEN THERAPEUTICS INCORPORATED (NASDAQ: OREX)
"Up 14.02% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/OREX.php
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The company’s Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.
OREX News:
February 21 - Arena Pharmaceuticals and Orexigen Therapeutics Look to Make Headway in Obesity Drug Market
The Paragon Report Provides Equity Research on Arena Pharmaceuticals & Orexigen Therapeutics
While the North American economy continues to stagnate, the obesity epidemic in the United States and Canada shows no signs of slowing. According to ObesityEpidemic.org, the statistics show that roughly 33% of the US population is obese and 67% of the US population is overweight. According to The Obesity Research Journal, by 2030, 86.3% adults will be overweight or obese and 51.1% will be obese. Looking to combat North America's growing obesity crisis -- and capitalize on a highly lucrative sector -- several biotechnology firms have been working to develop obesity drugs and treatments. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Access to the full company reports can be found at:
www.paragonreport.com/ARNA
www.paragonreport.com/OREX
Orexigen Therapeutics, Inc., a development stage company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Earlier this month the company reached an agreement with U.S. health regulators on the design of a heart-safety trial required for the approval of its experimental obesity drug. Orexigen plans to enroll about 10,000 patients in the placebo-controlled trial for demonstrating that the drug Contrave does not unacceptably increase the risk of major adverse cardiovascular events, Reuters reports.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
In a big month for obesity drug makers, Arena Pharmaceuticals Inc. said an FDA advisory committee will meet in the second quarter to discuss the company's resubmitted application for its weight-loss drug, lorcaserin.
In addition to lorcaserin, Arena Pharmaceuticals is focused on APD811, an internally discovered, orally available agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension.
GREEN ENDEAVORS LIMITED (OTCQB: GRNE)
"Up 125.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/GRNE.php
Green Endeavors, Inc., headquartered in Salt Lake City, Utah, is a holding company with operations in health & beauty. GRNE owns a majority interest in several Aveda™ based businesses.
GRNE News:
February 23 - Green Endeavors Retains Atlas Architects and Receives Funding Commitments for Its Proposed Aveda™ Experience Center
Green Endeavors, Inc. (OTCQB: GRNE), a majority owned subsidiary of Nexia Holdings, Inc. (OTC: NXHD), announced that its newly formed subsidiary Landis Experience Center, LLC (LEC) has made significant progress on its proposed Aveda™ Experience Center (EC).
Richard Surber, CEO of GRNE, stated, "I have received sufficient funding commitments to complete the construction and initial inventory requirements to open our proposed Aveda™ retail store in Salt Lake City's City Creek Development. Additionally, we have retained Atlas Architects which has completed an initial design of the floor plans. Atlas is projecting the completion of a full set of architectural plans in March. I expect the City of Salt Lake to pass off on the drawings by the end of March. We are projecting an opening date for the Aveda™ Experience Center by June 1, 2012; which will be just in time to prepare for back to school and the 2012 holiday season."
Mr. Surber continued, "After nearly 8 months of planning and negotiating, I expect to have a definitive lease signed by the end of next week. I have also conducted several interviews with potential hires that have Aveda™ experience. These prospective new hires will be responsible for managing the new store, as well as fine tuning our front desk and retail sales systems throughout our existing Landis Lifestyle Salons. I am looking to increase products sales system wide by at least $500,000 in the 12 months subsequent to the opening of the EC. Increased product sales will improve our profit margins. The margins on product sales are much higher than on service sales."
MELA SCIENCES INCORPORATED (NASDAQ: MELA)
"Up 11.14% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/MELA.php
MELA Sciences is a medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. The Company's flagship product, MelaFind®, is intended to be used when a trained dermatologist chooses to obtain additional information to help decide whether to biopsy certain indeterminate pigmented skin lesions. MelaFind has received approval from the U.S. Food and Drug Administration and is approved for use in the U.S. In addition, MelaFind has received the CE Mark and is approved for use in the European Union.
MELA News:
February 23 - MelaFind® Results Improve Detection of Melanoma, Study Shows
Study Published in Archives of Dermatology Shows Significant Impact of MelaFind on Detection of Melanoma
MelaFind, developed by MELA Sciences, Inc. (NASDAQ: MELA), was shown to improve melanoma detection in a study of 179 dermatologists. The average sensitivity of dermatologists before obtaining the MelaFind output was 69 percent, and the average sensitivity after obtaining the MelaFind output was 94 percent, according to a recent study published online in the Archives of Dermatology on February 20, 2012.
MelaFind, a non-invasive, multi-spectral computer vision system recently approved by the FDA, uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device analyzes the three-dimensional morphologic (i.e., structural) disorganization under the surface of the lesion and provides an unambiguous and easy to interpret output -- High Disorganization (Positive) or Low Disorganization (Negative) -- that a dermatologist can incorporate into the biopsy decision-making process.
At a continuing medical education conference, 179 practicing dermatologists were asked to evaluate a series of pigmented lesions selected from prior MelaFind studies. Biopsy decisions were recorded before and after the dermatologists received the MelaFind information.
"MelaFind was shown to increase dermatologist sensitivity from a baseline of 69 percent to a level of 94 percent, and it increased the percent of dermatologists that detected all of the melanomas in the series from 13 percent to 70 percent," said Darrell S. Rigel, MD, Clinical Professor of Dermatology at New York University Medical School and lead author of the study. "Consistent with other diagnostic tools, the information provided by this type of diagnostic device for pigmented lesions was integrated into all of the other factors used in making a biopsy decision but was not 'blindly' followed."
After obtaining the MelaFind information, participating dermatologists made more uniform biopsy decisions. In the study, specificity amongst participating dermatologists decreased overall as their sensitivity increased with MelaFind. However, on MelaFind negative lesions, the availability of the MelaFind information increased dermatologist specificity. According to the study, the MelaFind information resulted in a 17 percent reduction of biopsies of these histologically benign lesions.
"The study clearly demonstrated that MelaFind can provide significant clinical utility," added Dr. Rigel. Sensitivity, the ability to detect disease when disease is truly present in a population, and specificity, the ability to correctly rule-out disease when disease is truly absent, are the measures used to assess diagnostic performance.
MELA Sciences is executing a controlled and deliberate launch of MelaFind predominantly in the Northeastern U.S. and in several key cities throughout Germany. During this period, the company will work with the dermatology practices to train and assist them in using MelaFind appropriately and to incorporate its use successfully into their practices. This approach is appropriate for a first-of-a-kind breakthrough product and will serve as the basis for more widespread dissemination of MelaFind in the future.
DELTRON INCORPORATED (OTCBB: DTRO)
"Up 171.71% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/DTRO.php
Deltron acquires profitable businesses with strong management teams, substantial revenue and established market positions. Wholly owned subsidiary Blu Vu is a developer of proprietary closed circuit rebreather technology and components that go beyond conventional scuba systems to enable commercial and recreational divers to go deeper, stay underwater longer and recover faster. Wholly owned Elasco is a proven innovator in product manufacturing with a 30-year operating history, diverse customer base and vertically integrated manufacturing facility in Garden Grove, California.
DTRO News:
No recent news items for Deltron, Inc. (OTCBB: DTRO).
OBSCENE INTERACTIVE LLC (OTCBB: OBJE)
"Up 36.65% on Thursday"
Detailed Quote: www.otcpicks.com/quotes/OBJE.php
Obscene Interactive is an emerging global developer of social gaming applications. OBJE's cutting-edge technology platform enables its titles to be accessible to a broad audience of consumers all over the world, supporting multiple platforms for universal appeal. Obscene Interactive is focused on delivering the best in social gaming solutions to the mass market.
OBJE News:
February 23 - OBJE Targets Promising New Gaming Deals at Texas ACG Capital Connection Conference
As Obscene Interactive, LLC (OTCBB: OBJE) shifts focus to the multi-billion dollar interactive gaming sector, the company will target hot new emerging gaming developers this week at the Texas ACG Capital Connection Conference in Austin, Texas. The city of Austin has been dubbed the “Silicon Valley of Texas” for its reputation in breakout tech innovations.
The two-day event to be held on February 22-23 will provide OBJE’s executive leadership with the opportunity to connect with leading CEOs, CFOs, game developers, and business development executives from middle-market companies throughout the Southwest. The annual event boasts over 1000 participants, including prominent financial intermediaries and investors such as investment banks, venture capitalists and private equity firms.
OBJE CEO Paul Watson will be in attendance to scout trends in gaming and digital media and to network with some of the most innovative technology startups in the country as they come to seek capital to fund their vision. OBJE will vet companies for potential acquisition and joint ventures that can help the company rise to the top of the social and online gaming sphere.
|
